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Clinical Evaluation of a GP5/6-Based Luminex Assay Having Full
High-Risk Human Papillomavirus Genotyping Capability and an
Internal Control
D. T. Geraets,a K. Cuschieri,b M. N. C. de Koning,a L. J. van Doorn,a P. J. F. Snijders,c C. J. L. M. Meijer,c W. G. V. Quint,a M. Arbynd
DDL Diagnostic Laboratory, Rijswijk, the Netherlandsa; Scottish HPV Reference Laboratory, Royal Infirmary of Edinburgh, Edinburgh, United Kingdomb; Department of
Pathology, VU University Medical Center, Amsterdam, the Netherlandsc; Unit of Cancer Epidemiology, Scientific Institute of Public Health, Brussels, Belgiumd
The LMNX genotyping kit HPV GP (LMNX) is based on the clinically validated GP5/6 PCR, with a genotyping readout as an
alternative for the more established enzyme immunoassay (EIA) detection of 14 targeted high-risk human papillomavirus (HPV)
types. LMNX is additionally provided with an internal control probe. Here, we present an analysis of the clinical performance of
the LMNX using a sample panel and infrastructure provided by the international VALGENT (Validation of Genotyping Tests)
project. This panel consisted of cervical specimens from approximately 1,000 women attending routine screening, “enriched”
with 300 women with abnormal cytology. Cases were defined as women classified with cervical intraepithelial neoplasia (CIN)
grade 2 (CIN2) (n 102) or CIN3 (n 55) within the previous 18 months. Controls were women who had normal cytol-
ogy results over two subsequent screening rounds at a 3-year interval (n 746). The GP5/6-PCR EIA (EIA) was used as a
comparator assay and showed sensitivities of 94.1% and 98.2% for CIN2 and CIN3, respectively, with a clinical specificity of
92.4% among women aged>30 years. The LMNX demonstrated clinical sensitivities of 96.1% for CIN2 and of 98.2% for
CIN3 and a clinical specificity of 92.6% for women aged>30 years. The LMNX and EIA were in high agreement (Cohen’s
kappa 0.969) for the detection of 14 hrHPVs in aggregate, and no significant difference was observed (McNemar’s P 0.629).
The LMNX internal control detected 0.6% inadequate specimens. Based on our study results, we consider the LMNX, similarly to
the EIA, useful for HPV-based cervical cancer screening.
Human papillomavirus (HPV) tests that have been validatedfor use in a clinical setting usually target 13 or 14 genotypes.
These HPVs have been classified by the International Agency for
Research on Cancer (IARC) as carcinogenic, i.e., HPV16, HPV18,
HPV31, HPV33, HPV35, HPV39, HPV45, HPV51, HPV52,
HPV56, HPV58, andHPV59 (class 1), probably carcinogenic, i.e.,
HPV68 (class 2A), or possibly carcinogenic, i.e., HPV66 (class 2B)
(1). TheHybridCapture 2 (HC2;Qiagen,Hilden, Germany) assay
(2–4) and GP5/6 PCR-based enzyme immunoassay (EIA) kit
HPV GPHR (EIA; Diassay, Rijswijk, the Netherlands) (5–9) were
the first HPV tests to be clinically validated for primary screening
on the basis of longitudinal results from large screening studies
(10). Testing for high-risk HPV (hrHPV) nucleic acids is also use-
ful for triage of women with equivocal or mildly abnormal cytol-
ogy for colposcopy and as a test of cure of treatment (10).
Several novelHPV tests have been fully or partially validated by
showing noninferiority to HC2 or EIA and high reproducibility
(11), as has been extensively reviewed by Arbyn et al. (10) and
reported in additional studies (12–14). These tests usually detect
around 14 hrHPVs in aggregate, but some provide concurrent
(partial) genotype-specific information. Concurrent genotyping
for HPV16 and HPV18 could be beneficial for the triage of
hrHPV-positive women (15), as these HPV types have a higher
risk of causing cervical cancer than the other hrHPVs (16–19). The
value of genotyping of hrHPVs other than HPV16 and HPV18
(20, 21) is currently unknown, although genotyping can resolve
type-specific persistence issues more accurately than repeated
measurementswith a consensus test, whichmay assist in risk strat-
ification for women in screening populations and diagnostic set-
tings (22).
The LMNX Genotyping Kit GP HR (LMNX; Diassay BV,
Rijswijk, theNetherlands; previous versionmarketed as the digene
HPV Genotyping LQ Test by Qiagen, Hilden, Germany) (20, 23–
27), based on the clinically validated GP5/6 PCR assay (5–9),
offers an alternative readout method for the EIA. LMNX provides
high-throughput and full genotyping of the 14 high-risk (hr)HPV
types described earlier and has recently beenmodified to incorpo-
rate an internal control for a human DNA target to minimize the
chance of technical false-negative test results.
In the current study, theGP5/6-based PCREIA systemwas
firstly used to analyze a study panel of 1,300 cervical liquid cytol-
ogy samples. The study forms part of an international collabora-
tion for the clinical validation of HPV tests, which offer limited to
extensive genotyping: Clinical Validation of HPV Genotyping
Tests (VALGENT) (28). Here, we aimed to (i) compare the detec-
tion of 14 pooled hrHPVs by LMNX to detection by EIA for
women with high-grade (HG) cervical intraepithelial neoplasia
(CIN) and (ii) to evaluate the performance of the internal control
recently included in LMNX, which allows verifying the quality of
the specimen.
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MATERIALS AND METHODS
Clinical specimens. The second study panel prepared by the VALGENT
consortium (VALGENT-2) consisted of stored cervical specimens col-
lected from 1,000 consecutive women attending the Scottish cervical
cancer screening program between August and September 2012. In Scot-
land, women aged 20 to 60 years old are screened every 3 years by liquid-
based cytology using the classification system of the British Society for
Cervical Cytology (BSCC) (29; http://www.cancerscreening.nhs.uk
/cervical/publications/nhscsp01.html). This screening population was
“enriched” with specimens from 300women that were selected for abnor-
mal cytology, i.e., borderline nuclear change (n 100), mild dyskaryosis
(n  100), moderate dyskaryosis (n  57), and severe dyskaryosis (n 
43), in agreement with the VALGENT protocol (28). All cervical speci-
mens had been collected by trained health care workers based in health
care settings and were stored in PreservCyt ThinPrep medium (Hologic,
Marlborough, MA), in agreement with European guidelines (30). Ali-
quots were prepared from the residual specimen and distributed to the
laboratories participating in VALGENT by the Scottish HPV Reference
Laboratory, Royal Infirmary of Edinburgh.
Ethical approval. Favorable ethical opinion for the study was pro-
vided by the West of Scotland Research Ethics Office, reference 11/WS/
0038. Sample aliquots were labeled with a nonidentifiable study number
only prior to dissemination to participating laboratories.
Clinical outcomes. Women with abnormal cytology were managed
in accordance with guidelines of the United Kingdom National Health
Service Cervical Screening Programme (NHSCSP) standard of care
(http://www.cancerscreening.nhs.uk/cervical/publications/nhscsp01
.html), which are in agreement with European recommendations (31).
Biopsy specimens were taken as routinely indicated and histologically
graded according to the cervical intraepithelial neoplasia (CIN) clas-
sification system (32).
Women with high-grade cervical disease (case group) were defined as
those diagnosed with histologically confirmed CIN2, CIN3, or invasive
squamous cell carcinoma (CIN2) within 18 months after collection of
the cervical specimen. Diagnosis of CIN3 or invasive squamous cell car-
cinoma (CIN3) was used as an additional disease outcome. Women
without high-grade disease (control group) were those who had a normal
cytology result in the current cervical specimen as well as in the specimen
collected during the previous screening round approximately 3 years be-
fore. Among women without high-grade disease, those aged 30 years
constituted the primary cohort for calculation of clinical specificity of the
evaluated HPV tests in accordance with international guidelines (11).
Sample processing and HPV testing.Nucleic acidswere isolated from
500 l of the received aliquot on a MagNA Pure 96 instrument (Roche
Diagnostics, Almere, the Netherlands) using a MagNA Pure 96 DNA and
Viral NA Large Volume kit (Roche) and collected in 100l elution buffer
in accordance with the manufacturer’s instructions.
The GP5/6 EIA kit (EIA kit HPV GP HR; Diassay, Rijswijk, the
Netherlands) was used according to the kit insert instructions. Briefly, 10
l of extracted DNA was amplified by the GP5/6 broad-spectrum
primer set. A probe cocktail specific for 14 hrHPV genotypes (i.e., HPV16,
HPV18, HPV31, HPV33, HPV35, HPV39, HPV45, HPV51, HPV52,
HPV56, HPV58, HPV59, HPV66, and HPV68) hybridized to 5 l of
GP5/6 amplimers in an enzyme immunoassay (EIA). This assay does
not identify HPV genotypes individually.
A second aliquot of GP5/6 amplification product (4l) was geno-
typed by the use of the commercially available LMNX Genotyping kit
HPV GP HR (LMNX) (Diassay; previous version marketed as the digene
HPVGenotyping LQ Test by Qiagen, Hilden, Germany) according to the
manufacturer’s instructions (20, 23–27).
In short, GP5/6 amplification products were hybridized to HPV
type-specific probes attached to color-coded beads, targeting the same 14
hrHPVs as the EIA. LMNX targets four additional possibly hrHPV types
(i.e., HPV26, HPV53, HPV73, and HPV82), but these were not included
in the assessment of the clinical performance. Readout was performed on
a Luminex 100 IS system (Luminex Corporation, Austin, TX) according
to the instrument settings specified in the kitmanual. Two general thresh-
olds for the type-specific probes were evaluated in a previous study in
relation to the established reverse line blot assay, i.e., median fluorescent
intensities (MFI) of 30 and 100 (23). Based on a training panel (data not
presented), a general cutoff MFI of 50 (recommended in the kit manual)
provided optimal agreement with the EIA for hrHPV detection and was
therefore used in this study.
The use of one Luminex 100 IS system (Luminex) combined with two
MagNA Pure 96 instruments (Roche) for extraction and four GeneAmp
PCR System 9700 modules (Applied Biosystems) for PCR allows high-
throughput processing of approximately 3,000 specimens per week.
Internal control development. An internal control probe targeting a
313-bp byproduct coamplified by the GP5/6 primers, similar to that
described in reference 33, has recently been incorporated into the LMNX
assay. This coamplified fragment was originally visualized on an agarose
gel, excised, purified, and determined by sequence analysis to be a human
DNA fragment located on chromosome 14 (data not presented). The
benefit of the use of this internal control strategy is that no modifications
had to be made to the composition and test conditions of the GP5/6
PCR. Addition of separate primers for human DNA amplification (e.g.,
beta-globin) could have had an impact onHPV amplification due to com-
petition between primer sets (34). The internal control probe was added
to the mix of HPV-specific probes of the LMNX set at a threshold MFI
of 50.
Statistics. Frequencies, distributions, and percentages with 95%bino-
mial confidence intervals were computed. The two-tailedMcNemar’s test
was used for comparison of EIA and LMNX hrHPV positivity rates, and
the level of agreement was determined using Cohen’s kappa statistics. The
clinical sensitivity and specificity, calculated using the definitions of dis-
ease outcomes, of LMNX were compared to those of the EIA using a
noninferiority score test (11). We applied a sensitivity threshold of0.90
and a specificity threshold of 0.98 relative to those of GP5/6 EIA,
under the null hypothesis of inferiority (11). The level of statistical signif-
icance was set at 0.05. Analyses were performed using SPSS version 19.0.
RESULTS
Study population characteristics. In total, 1,298 of the 1,300 cer-
vical samples of the VALGENT-2 panel had sufficient material to
be included in this study, since 2 specimens (from the screening
population)were not included in the shipment. The average age of
women in the overall population was 38 years (range, 18 to 68),
with a significant proportion (32.3%) below the age of 30 years. In
the screening population (n 998), cytology scorings were nega-
tive (89.8%), borderline nuclear change (5.4%), mild dyskaryosis
(3.8%), moderate dyskaryosis (0.5%), and severe dyskaryosis
(0.5%). The colposcopic or histologic diagnoses for women re-
ferred for diagnostic follow-up within 18 months, originating
from the screening or enriched population, were normal (n 63),
koilocytosis (n  11), CIN grade 1 (CIN1) (n  25), CIN2 (n 
47), CIN3 (n  52), and invasive cervical squamous cell carci-
noma (ICC) (n 3) (Table 1). A total of 102 women had CIN2,
and 55 among them had CIN3, whereas 746 subjects had two
subsequent normal cytology results.
Characterization of the VALGENT study panel by GP5/
6-PCR EIA. The study panel contained 387 (29.8%) women
who were hrHPV positive by the GP5/6-PCR EIA, of whom
169 were from the screening cohort (n 998) and 218 were from
the enriched group (n 300). The clinical sensitivities for CIN2
and CIN3 of the GP5/6-PCR EIA system were 94.1% (95%
confidence interval [CI], 87.1% to 97.6%) and 98.2% (95% CI,
89.0% to 99.9%), respectively (Table 2). The clinical specificity for
CIN1 was 92.4% (95% CI, 90.0% to 94.3%) for women aged
Clinical Evaluation of GP5/6 Luminex Genotyping Test
November 2014 Volume 52 Number 11 jcm.asm.org 3997
 o
n
 January 14, 2015 by UNIVERSITY O
F EDINBURG
H
http://jcm.asm.org/
D
ow
nloaded from
 
30 years (n 633). For women of all ages, the clinical specificity
was 90.3% (95% CI, 87.9% to 92.3%) (n 746).
Comparison of HPV detection by LMNX and EIA. The
LMNX was positive for at least 1 of 14 hrHPVs in 390 (30.0%) of
the 1,298 samples tested in total, which was not significantly dif-
ferent from the overall positivity rate by the EIA (McNemar’s P
0.629). Both assays were in high agreement for hrHPV detection
(kappa 0.969) (Table 2). The hrHPV positivity rates by LMNX
were 17.1% in the screening cohort (n  998) and 73.0% in the
enriched group (n 300).
HPV results by EIA and LMNX were discordant in only 17 of
1,298 (1.3%) specimens tested in total. Seven women were posi-
tive by EIA but negative by LMNX. None of these women were
diagnosed with histologically confirmed high-grade cervical dis-
ease. For these seven women, cytology results were negative (n
4), borderline nuclear changes (n 1), mild dyskaryosis (n 1),
and moderate dyskaryosis but with koilocytosis diagnosed in fol-
low-up histology (n 1). In contrast, LMNX detected hrHPV in
10 women who were negative by EIA. Among these 10 women, 5
had normal cytology, 3 had borderline nuclear changes, and 2 had
TABLE 1 Characteristics of the two study populations, i.e., 998 women consecutively attending a cervical cancer screening program (screening
population) and 300 women referred for abnormal cytology (enriched population)
Characteristic
Screening population Enriched population Overall population
n % n % n %
Age
Mean age in yrs (minimum–maximum) 40 (20–68) 31 (19–62) 38 (19–68)
30 yrs 746 74.7 133 44.3 879 67.7
30 yrs 252 25.3 167 55.7 419 32.3
Clinical outcome (worst diagnosis within 18 mos)
Normal cytology, no histology 892 89.4 0 0.0 892 68.7
Normal cytology in current and previous screening round 746 74.7 0 0.0 746 57.5
Abnormal cytology, no histology 66 6.6 139 46.3 205 15.8
Normal colposcopic impression or normal histology 23 2.3 40 13.3 63 4.9
Koilocytosis 3 0.3 8 2.7 11 0.8
CIN1 1 0.1 24 8.0 25 1.9
CIN2 5 0.5 42 14.0 47 3.6
CIN3 8 0.8 44 14.7 52 4.0
ICC 0 0.0 3 1.0 3 0.2
Total 998 100 300 100 1,298 100
TABLE 2 Comparison of LMNX to EIA for hrHPV detection among women in the overall study population stratified for CIN2 and CIN3
outcome and forCIN1 among women aged30 yearsa
Study population EIA result
No. of women with LMNX resultb
Clinical performance characteristics
[% (95% CI)]
Noninferiority
scorecPositive Negative Total EIA LMNX
Overall population Positive 380 7 387
(n 1,298) Negative 10 901 911
Total 390 908 1,298
CIN2 (n 102) Positive 96 0 96 Sensitivity (CIN2): Sensitivity (CIN2): P 0.001
Negative 2 4 6 94.1 (87.1–97.6) 96.1 (89.7–98.7)
Total 98 4 102
CIN3 (n 55) Positive 54 0 54 Sensitivity (CIN3): Sensitivity (CIN3): P 0.007
Negative 0 1 1 98.2 (89.0–99.9) 98.2 (89.0–99.9)
Total 54 1 55
CIN1 (30 yr) Positive 46 2 48 Specificity: Specificity: P 0.007
(n 633) Negative 1 584 585 92.4 (90.0–94.3) 92.6 (90.2–94.4)
Total 47 586 633
a The clinical sensitivity (for CIN2 and CIN3) and specificity of the LMNX were compared with those of the EIA using a noninferiority score test. The clinical sensitivity was
calculated among women diagnosed with CIN2 (CIN2, CIN3, or invasive squamous carcinoma) and CIN3 (CIN3 or invasive squamous carcinoma) within 18 months of
follow-up, and clinical specificity was determined among women aged30 years withCIN1 (normal cytology during the current as well as the previous screening round 3 years
earlier).
b A positive LMNX result represents detection of one or more of the following 14 HPV genotypes: HPV16, HPV18, HPV31, HPV33, HPV35, HPV39, HPV45, HPV51, HPV52,
HPV56, HPV58, and HPV59 (12 HPVs classified by the IARC as carcinogenic; class 1) and, additionally, HPV68 (class 2A) and HPV66 (class 2B).
c A sensitivity threshold of at least 90% and a specificity threshold of at least 98% relative to that of the EIA was applied in a noninferiority score test. The null hypothesis of
inferiority of the LMNX was rejected if P 0.05.
Geraets et al.
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mild/moderate dyskaryosis. The latter two women were diag-
nosedwithCIN2 in follow-up histology.When specimens of these
two women with underlying high-grade disease were retested by
EIA and LMNX, one tested positive for hrHPV by both EIA and
LMNX whereas one remained positive by LMNX only.
HPV genotyping by LMNX. Among the 390 hrHPV samples
positive by LMNX, 68.5% contained a single HPV strain and
31.5% had multiple HPV strains. The proportions of multiple
genotypes in HPV-positive smears differed according to clinical
outcome, i.e., 34.6% for CIN1/koilocytosis, 29.5% for CIN2,
41.2% for CIN3, and 0% for ICC. The HPV genotyping results
among the different groups are provided in Table S1 in the sup-
plemental material.
Themost prevalent types among the 390HPV-positive women
were HPV16 (28.5%), HPV31 (13.8%), and HPV66 (12.8%). In
women diagnosed with CIN2 within 18 months (n 44), HPV16
(50.0%), HPV18 (15.9%), and HPV31 (15.9%) were the most
frequently detected types. Comparatively, in women with CIN3
(n 51), the most prevalent types were HPV16 (52.9%), HPV31
(35.3%), andHPV33 (13.7%). Three womenwere diagnosedwith
ICC; all three had a single HPV16-positive smear. Table 2 details
the 10 samples that were LMNX positive but EIA negative. These
samples contained single infections by HPV33, HPV39, HPV45,
HPV51 (n 3), HPV52, HPV59 (n 2), and HPV68.
Clinical performance LMNX and EIA. LMNX was compared
to EIA for the detection of women diagnosed with high-grade
disease within 18 months, i.e., CIN2 and CIN3 (Table 2).
LMNXdetected 98/102 (96.1%; 95%CI, 89.7% to 98.7%) women
with CIN2, and EIA was positive in 96/102 (94.1%; 95% CI,
87.1% to 97.6%) women with CIN2. In this series, the clinical
sensitivity of LMNX for CIN2 was noninferior to that of EIA
(noninferiority score test P  0.001). The clinical sensitivity of
LMNX for CIN3 (54/55, 98.2%; 95% CI, 89.0% to 99.9%) was
also noninferior to that of EIA (54/55, 98.2%; 95% CI, 89.0% to
99.9%) (noninferiority score test P 0.001).
Despite high clinical sensitivity, EIA and LMNX were negative
for six and four womenwith high-grade disease (CIN2), respec-
tively. Two women with CIN2 were HPV negative by EIA, but
LMNX showed single infections with HPV52 and HPV59. In four
womenwith high-grade disease, i.e., CIN2 (n 3) andCIN3 (n
1), EIA and LMNX were both negative for the presence of 14
hrHPVs. Three of these four women had single infections with
types other than the 14 hrHPVs that were targeted by both
assays, i.e., HPV53 (CIN3; by LMNX), HPV82 (CIN2; by
LMNX), and HPV70 (CIN2; by sequence analysis). All these
identified types have been classified as possibly carcinogenic by
IARC (class 2B) (1).
The clinical specificity of LMNX for CIN2 among women
aged 30 years (586/633, 92.6%; 95% CI, 90.2% to 94.4%) was
also noninferior to that of EIA (585/633, 92.4%; 95%CI, 90.0% to
94.3%) (noninferiority score test P 0.001) (Table 2). The clini-
cal specificities of LMNX and EIA among women of all ages (n
746) were 90.8% (95% CI, 88.4% to 92.7%) and 90.3% (95% CI,
87.9% to 92.3%), respectively (noninferiority score test P 
0.001).
EIA and LMNXalso showed similar clinical performance char-
acteristics independently of study population (screening popula-
tion versus enriched population) and subsequently of age category
(younger than 30 years versus 30 years of age and older), as shown
in Table 3. The hrHPV positivity in women from the screening
population without underlying disease was dependent on age, ir-
respective of the HPV test used. hrHPV was more prevalent
among women younger than 30 years old than among those 30
years of age and older, i.e., 19.5% versus 7.4% (P  0.001) by
LMNX and 21.2% versus 7.6% (P 0.001) by EIA.
Assessment of specimen quality by internal control. The
LMNX internal control probewas positive for humanDNA in 968
(97.0%) of the screening specimens (n 998). Among these spec-
imens of sufficient quality, 158 (15.8%) were positive and 810
(81.2%) were negative for one ormore of the 18HPVs targeted by
TABLE 3 hrHPV positivity rate by EIA and LMNX in relation to clinical outcome, i.e., among women who had histologically confirmed high-grade
disease (CIN2 or CIN3) in the follow-up and women who had normal cytology in the current and the previous screening round (CIN1)a
Study population and
age group
CIN2 CIN3 CIN1
EIA positive LMNX positiveb EIA positive LMNX positiveb EIA positive LMNX positiveb
% n/N % n/N % n/N % n/N % n/N % n/N
Screening populationc 100 13/13 100 13/13 100 8/8 100 8/8 9.7 72/746 9.5 69/746
30 yrs 100 5/5 100 5/5 100 2/2 100 2/2 7.6 48/633 7.4 47/633
30 yrs 100 8/8 100 8/8 100 6/6 100 6/6 21.2 24/113 19.5 22/113
Enriched populationd 93.3 83/89 95.5 85/89 97.9 46/47 97.9 46/47 n/a n/a n/a n/a
30 yrs 92.3 36/39 94.9 37/39 95.5 21/22 95.5 21/22 n/a n/a n/a n/a
30 yrs 94.0 47/50 96.0 48/50 100 25/25 100 25/25 n/a n/a n/a n/a
Overall population 94.1 96/102 96.1 98/102 98.2 54/55 98.2 54/55 9.7 72/746 9.2 69/746
30 yrs 93.2 41/44 95.5 42/44 95.8 23/24 95.8 23/24 7.6 48/633 7.4 47/633
30 yrs 94.8 55/58 96.6 56/58 100 31/31 100 31/31 21.2 24/113 19.5 22/113
a Positivity rates are stratified by population (screening, enriched, or overall) and subsequently by age group (women 30 years and older or women younger than 30 years old).
CIN1, women who had normal cytology during the current as well as the previous screening round 3 years earlier; CIN2, women diagnosed with CIN2, CIN3, or invasive
squamous carcinoma within 18 months of follow-up; CIN3, women diagnosed with CIN3 or invasive squamous carcinoma within 18 months of follow-up; n/N, number of
women with the indicated disease characteristics and test result/total number of women; n/a, not applicable.
b A positive LMNX result represents detection of one or more of the following 14 HPV genotypes: HPV16, HPV18, HPV31, HPV33, HPV35, HPV39, HPV45, HPV51, HPV52,
HPV56, HPV58, and HPV59 (12 HPVs classified by IARC as carcinogenic; class 1) and, additionally, HPV68 (class 2A) and HPV66 (class 2B).
c Screening population: a study population of women consecutively attending a cervical cancer screening program.
d Enriched population: a study population of women referred for abnormal cytology.
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LMNX. The internal control was negative in 30 samples, of which
24 (2.4%)were positive for HPV andwere therefore considered of
adequate quality. Six specimens (0.6%) were negative for both
HPV and the internal control by LMNXandwere therefore scored
as inadequate.However, additionalHPV testing by sequence anal-
ysis demonstrated the presence of HPVs not targeted by LMNX in
three of these six samples, i.e., HPV11, HPV59 (a variant not tar-
geted by the LMNX probe), and HPV90.
DISCUSSION
The clinically validated GP5/6-PCR EIA system was used to
analyze this large study panel, which was composed as part of an
international collaboration for the clinical validation of HPV
genotyping tests (VALGENT) (28). The observed high clinical
sensitivity of the EIA (94.1%) is in line with a meta-analysis of
previous validation studies (94.5%; range, 94% to 100%) (10) and
provides further support for the use of the EIA as the reference test
in the VALGENT study protocols (28).
The LMNX test, which uses the same GP5/6 PCR primers
and conditions as the EIA, showed a clinical performance that was
noninferior to the EIA for the respective 14 hrHPV genotypes.
The clinical specificity of the EIA (among women aged 30
years; 92.4%) was slightly lower than that previously reported
(94.8%; range, 86% to 96%) (10). The EIA positivity was higher
among cytologically normal women below 30 years of age (21.2%)
than among those aged 30 years and older (7.6%). A relatively low
clinical specificity of HPV-based screening among young women
has been observed previously (35). Therefore, guidelines for clin-
ical validation of HPV tests have been defined for a screening
population of women 30 years of age and older only (11).
Internal amplification controls aim to identify unsatisfactory
specimens which may be the cause of false HPV-negative test re-
sults. The LMNXwas upgraded with an internal control probe for
a fragment of humanDNA intrinsically coamplified byGP5/6
primers (33). In the screening population (n 998), 30 specimens
(3.0%) had a negative result for the internal control. Of these, 24
(2.4%) were positive for HPV. The negative result for the internal
control probe was most likely related to PCR competition with
HPVs present in the sample with a high load, since HPV DNA is
preferentially amplified compared to human DNA by the
GP5/6 primers. Specimens with these results can therefore be
considered of adequate quality for hrHPV testing in a clinical set-
ting. The remaining six samples (0.6%) were negative for both
HPV and human DNA and were interpreted as invalid. These
invalid results can be caused by inadequate specimen collection or
by untargeted HPVs (confirmed by sequence analysis) present in
high viral loads, which are preferentially amplified, resulting in an
absent internal control signal (PCR competition). However, it
should also be noted that a positive result for the internal control
(i.e., the presence of human cells) does not provide full reassur-
ance of correct sampling of indicator cells, i.e., of epithelial cells at
the squamocolumnar junction. Also, there is currently no defined
adequacy threshold for the quantity of human DNA that should
be detected by a HPV test with an internal control.
The LMNX has the option of full genotyping of hrHPV types
(23), including HPV16 and HPV18, which might be relevant for
triage (15). The value of full genotyping is still unclear, but it
might help in identifying type-specific persistent HPV infections.
A persistent hrHPV infection is a known risk factor for the devel-
opment of cervical (pre)cancer (22), and genotyping could there-
fore be of use in follow-up testing of screen-positive women. In
addition, persistence of a hrHPV infection in women treated for
high-grade cervical lesions could be indicative of residual or re-
current disease (36).
This study had several strengths. The composition and size of
the VALGENT-2 study population in terms of cases (mainly from
an enriched population) and controls (from a screening popula-
tion) facilitated an accurate estimation of clinical performance of
HPV tests, using a limited number of samples. Without the en-
richment, a screening population of 10,000 to over 20,000 women
would be needed to identify about 100 CIN2 cases. Further-
more, a well-validated HPV test, i.e., the EIA, was used as a refer-
ence assay, to which all (genotyping) assays performed on the
VALGENT-2 panel will ultimately be compared. Also, clinical
outcome data are well registered in the Scottish screening pro-
gram, whichwill allow a longitudinal evaluation ofHPV tests over
time. Finally, an advantage is that all HPV assays are performed on
the original cervical specimen in VALGENT-2. This facilitates
evaluations and comparisons of the complete test system (e.g.,
specimenprocessing, amplification, and readout), since all aspects
of the diagnostic chain determine the final test result.
However, our study also had some limitations. International
guidelines for clinical validation of hrHPV tests stipulate that sam-
ples should be derived fromwomen in a screening cohort tested by
a clinically validated hrHPV test, either combined with or not
combined with cytology (11). The current study utilized a screen-
ing cohort based on cytology alone. Since the identification of
CIN2 cases in VALGENT-2 was driven by cytology, which is
knownbe a clinically less sensitive technology, an advantagemight
be given to an HPV test with a relatively low sensitivity. The
VALGENT-2 cohort will be followed up to identify CIN2 cases
that may develop over time in order to identify missed cases. In
addition, an enriched population of 300 women with abnormal
cytology was included to find a sufficient number of CIN2 cases
while avoiding the necessity of testing the whole population from
which these 300 women were selected. Although this allows clin-
ical validation according to international guidelines (11), the pos-
itive predictive value (PPV) of the evaluated tests is not relevant
without appropriate statistical weighting. Furthermore, the spec-
ificity of hrHPV tests should be determined in a screening cohort
of women at least 30 years of age. In our study, 25.3% of the
screening population was below the age of 30. Nevertheless, the
LMNX assay is based on the same primers and PCR procedure as
EIA; therefore, it is highly unlikely that this assay would deviate
from the EIA on another sample set. Finally, in addition to the
fulfilled criteria for diagnostic accuracy by LMNX, the interna-
tional guidelines (11) also require investigation of intralaboratory
reproducibility in time and interlaboratory agreement. These
were not investigated in the current study, since LMNXpreviously
showed an intralaboratory reproducibility of at least 95% on a
series of artificial and clinical samples that were assayed at differ-
ent time points, by different technicians, and using different kit
lots (described in the kit manual). High interlaboratory agree-
ment (kappa  0.987) was observed in a previous study (23). In
summary, two HPV tests based on the GP5/6 PCR, i.e., EIA
and LMNX, demonstrated equivalent clinical performance char-
acteristics. The EIA and LMNX have the advantage that they are
both based on the extensively clinically validated GP5/6 PCR.
In addition, the LMNX has high-throughput and full genotyping
capability, and test performance and sample quality can be veri-
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fied through the use of the internal control. Based on our data,
both the EIA and LMNX are suitable options for HPV-based cer-
vical cancer screening.
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